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Abstract
Stem cells are emerging as a therapeutic option for incurable diseases, such as Amyotrophic Lateral Sclerosis (ALS).
However, critical issues are related to their origin as well as to the need to deepen our knowledge of the therapeutic
actions exerted by these cells. Here, we investigate the therapeutic potential of clinical-grade human neural stem cells
(hNSCs) that have been successfully used in a recently concluded phase I clinical trial for ALS patients (NCT01640067).
The hNSCs were transplanted bilaterally into the anterior horns of the lumbar spinal cord (four grafts each, segments
L3–L4) of superoxide dismutase 1 G93A transgenic rats (SOD1 rats) at the symptomatic stage. Controls included
untreated SOD1 rats (CTRL) and those treated with HBSS (HBSS). Motor symptoms and histological hallmarks of the
disease were evaluated at three progressive time points: 15 and 40 days after transplant (DAT), and end stage. Animals
were treated by transient immunosuppression (for 15 days, starting at time of transplantation). Under these conditions,
hNSCs integrated extensively within the cord, differentiated into neural phenotypes and migrated rostro-caudally, up
to 3.77 ± 0.63 cm from the injection site. The transplanted cells delayed decreases in body weight and deterioration of
motor performance in the SOD1 rats. At 40DAT, the anterior horns at L3–L4 revealed a higher density of motoneurons
and fewer activated astroglial and microglial cells. Accordingly, the overall survival of transplanted rats was significantly
enhanced with no rejection of hNSCs observed. We demonstrated that the beneficial effects observed after stem cell
transplantation arises from multiple events that counteract several aspects of the disease, a crucial feature for
multifactorial diseases, such as ALS. The combination of therapeutic approaches that target different pathogenic
mechanisms of the disorder, including pharmacology, molecular therapy and cell transplantation, will increase the
chances of a clinically successful therapy for ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive dis-
ease that targets primarily motor neurons (MNs) and leads
to fatal paralysis1,2. The molecular mechanisms that initiate
and drive the inherent neurodegenerative process are lar-
gely unknown. Recent reports strongly implicate neuroin-
flammatory processes, such as astrogliosis, microgliosis and
the infiltration of T lymphocytes, in the progressive
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degeneration of MNs:3–5 These non-cell-autonomous
mechanisms are promising therapeutic targets.
ALS is a multifactorial disorder that involves genetic as
well as environmental factors. Most (90–95%) of ALS
forms are sporadic (sALS), while about 10% of cases are
familial (fALS) and are associated with mutations in
specific genes, such as superoxide dismutase 1 (SOD1,
20% of fALS), TARDBP and FUS (5% of fALS) and
C9ORF72 (40% of fALS)6–8. SOD1 was the first mutated
protein that was correlated with the development of ALS9,
and it has been leveraged to generate animal models of
ALS—these include the SOD1 rats used here10, which
reproduce many of pathological and symptomatic features
of the human disorder and have been used for developing
therapeutic strategies, such as stem-cell transplantation.
Preclinical studies show that intraspinally transplanted
human neural stem cells (hNSCs) provide trophic support
to damaged cells, and also modulate the immune cell
environment, thus acting on disease mechanisms at
multiple levels;11–20 based on these results, the approach
was translated into the clinic, and two phase I21–23 and
phase II24,25 studies with use of hNSCs have been suc-
cessfully completed. The exact mechanisms through
which these cells exert their beneficial effects have not
been completely identified. Moreover, the use of hNSCs
derived from different CNS sources, using a variety of
methods, further confounds the direct comparisons of
findings from different labs. For clinical applications, a
standardised protocol that guarantees the reproducibility,
safety and efficacy of hNSCs is of utmost importance. Our
group has established a Cell Factory and Biobank at the
Hospital Santa Maria in Terni that is currently producing
hNSC lines from the foetal brain, using methods26 that are
fully compliant with current Good Manufacturing Prac-
tice (cGMP) guidelines, and are approved for clinical
applications by the Italian Medicine Agency (AIFA, aM
154/2018). The cell lines are characterised by a con-
solidated paradigm to assess their stemness and safety.
Consistent with this rigorous approach, the hNSCs have
been successfully used in the phase I trial for ALS
patients23, EudraCT 2009–014484–39 NCT01640067),
and are also currently being evaluated in a phase I study
for the treatment of Secondary Progressive Multiple
Sclerosis (EudraCT 2015–004855–37 NCT03282760).
As a complement to the phase I trial, and preliminary to
phase II, we evaluate here the therapeutic potential of
using a GMP-grade hNSC line in the SOD1 rat model of
ALS. hNSCs were delivered by intraspinal cord trans-
plantation, using the same strategy as for ALS
patients23,24. Because we intended to unveil the role
played by hNSCs in delaying neural degeneration, e.g., by
modulating neuroinflammation11, we also evaluated the
symptomatic hallmarks of ALS, together with astrogliosis
and microgliosis, at different stages of disease progression
Results
Hallmarks of symptomatic progression in SOD1 rats
We evaluated disease progression in SOD1 rats by
monitoring the gradual deterioration of the motor system
as reflected by rotarod performance, motor score and
weight assessment, in n= 22 SOD1 rats (CTRL) com-
pared with n= 9 wild-type (WT) animals27–29. This ana-
lysis led us to identify the following four subsequent
clinical stages (Fig. 1a), based on the worsening of
symptoms:
(i) Early-symptomatic stage (ESS): this phase started
with subtle decrease in limb control (resulting in a
5% reduction in the motor score) and/or a two
consecutive failures of the rotarod test in the same
week. These changes occurred variably between
P92 and P115 (Fig. 1).
(ii) Mid-symptomatic stage (MSS): the symptoms
became gradually more evident during the
following month (~27 days after ESS; Fig. 1a), at
the end of which a decline in the weight of SOD1
rats, due to denervation-induced muscle atrophy,
started to become evident, (peak body weight at
21 days after ESS, orange arrow in Supplementary
Fig. 1A). Concomitantly, motor impairments were
now overt and stable, with a significant decrease in
the motor and rotarod performance scores relative
to the scores recorded for ESS (18%, p < 0.05 vs.
WT rats, orange arrow in Supplementary Fig. 1B;
and 25%, p < 0.01 vs. WT, orange arrow in
Supplementary Fig. 1C, respectively).
(iii) Late-symptomatic stage (LSS): transition from
MSS to LSS was characterised by a rapid decline
of weight and motor functions (Fig. 1a). At
40 days after ESS, the body mass was reduced by
10% (red arrows in Supplementary Fig. 1A) and
the performance on both motor tests was
decreased by 50% (red arrows in Supplementary
Fig. 1B, C). At about 60 days after ESS, SOD1 rats
displayed minimal motility and were unable to
perform the rotarod challenge (Supplementary
Fig. 1A–C).
(iv) End stage (E-ST): the day of E-ST was established
by the loss of the righting reflex (∼70 days after
ESS, Fig. 1a).
The day of transplantation was established as that day
when early motor symptoms first appear (referred to as
day 0, occurring within the ESS, at ~P105-P115; Fig. 1a
and yellow arrows in Supplementary Fig. 1A–C). SOD1
rats received four bilateral injections of hNSCs (hNSC
group, a total of 400,000 cells/animal, n= 15), or of only
HBSS (HBSS group, n= 15) into the anterior horn of the
lumbar spinal cord (L3–L4; Fig. 1b, c). Another control
group of SOD1 rats did not receive any surgical procedure
(CTRL group, n= 22).
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Fig. 1 Experimental plan and migration of transplanted hNSCs. a Experimental plan: rats were transplanted with hNSCs or HBSS when showed
the initial symptoms of the disease (ESS), age-matched not-transplated controls were also analysed. Behavioural test was performed for all the
durations of animals life. Histological analysis of the spinal cord was performed at 15DAT, 40DAT and at E-ST, that approximately correspond to MSS,
LSS and E-ST. b Schematic showing the transplant strategy and migration of hNSCs (green dots). c Schematic representation of the spinal cord
organisation. hNSC or HBSS were transplanted into the anterior horns (asterisk) and were able to radially migrate into the anterior funiculus (red) and
the lateral funiculus (blue). d Injection site with an evident cluster of grafted hNSCs (huN+) in the anterior horn of an animal at 40DAT. e At E-ST
hNSCs (huN+) reached a higher grade of dispersion into the parenchyma. f, g Charts showing the differences in hNSCs migration (f) and survival (g)
at 15, 40DAT or E-ST. ESS early-symptomatic stage, MSS mid-symptomatic stage, E-ST end stage, DAT days after transplantation, a.f. anterior funiculus,
a.h. anterior horn. Scale bars: 100 μm
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Histological analysis of the spinal cord was performed at
three different time points (Fig. 1a): 15 days after trans-
plantation (15DAT) during the MSS, 40DAT during the
LSS and at E-ST.
Transplanted hNSCs survive, migrate and differentiate in
the spinal cord of SOD1 rats
Viable hNSCs grafts (huN+, Fig. 1d–e) were found in
all animals. At 15 and 40DAT, most of hNSCs were
integrated into laminae VIII–IX of the anterior horns (Fig.
1c, d, AH) and few had migrated into the lateral and
anterior funiculi (Fig. 1d, AF). At E-ST, huN+ cells were
dispersed within the spinal cord and occurred individually
(not clustered, Fig. 1e); the cells had migrated extensively
along the rostro-caudal axis of the cord, from the thoracic
and sacral cord segments (1.69 ± 0.47 cm at 15DAT,
1.02 ± 0.39 cm at 40DAT and 3.77 ± 0.63 cm at E-ST,
Fig. 1f).
A high percent of the transplanted cells had survived,
and were detected at all three time points of analysis
(53.29 ± 32.34% at 15DAT; 77.81 ± 12.89% at 40DAT; and
53.65 ± 19.41% at E-ST—Fig. 1g, n= 3/time point). At
each time point, we also detected a similar fraction of
transplanted cells that were actively proliferating (Ki67+
cells: 9.11 ± 2.5% at 15DAT, 14.1 ± 4.3% at 40DAT and
15.2 ± 2.1% at E-ST; Fig. 2a, b), suggesting that new pro-
genitors were generated in vivo. Transplanted hNSCs
(Fig. 2a, b) expressed Nestin (26.9 ± 7.3% at 15DAT;
21.7 ± 7.7% at 40DAT; and sporadic at E-ST) and differ-
entiated into astroglia (GFAP+: 25 ± 4.7% at 15DAT,
20.5 ± 7.7% at 40DAT and 34.4 ± 3% at E-ST), neurons
(β-Tub III+, 16.1 ± 2.2% at 15DAT, 10.7 ± 5.4% at
40DAT and 4.5 ± 2% at E-ST) and oligodendrocyte pre-
cursors (PDGFRa+: 9.6 ± 3.7% at 15DAT; 17.6 ± 2.9% at
40DAT; and 9.4 ± 1.6% at E-ST). These data indicate that
hNSCs efficiently survive, transiently proliferate and dif-
ferentiate in the spinal cord of SOD1 rats.
Transplanted hNSCs prolong survival and delay the
progression of motor symptoms
The median survival time for hNSCs-transplanted rats
was 83.5 days, ~23 days longer than the control groups,
which had median survival times of 60.5 days (CTRL
animals, HR: 0.08; 95% CI= 0.01–0.65; p= 0.018) and
57.0 days (HBSS group, HR: 0.08; 95%CI= 0.01–0.72; p=
0.024, see Fig. 3a). The curves for the two control groups
were overlapping (HR: 0.94; 95% CI= 0.31–2.79;
p= 0.905).
Disease progression was significantly delayed in hNSCs-
transplanted animals, relative to CTRL and HBSS-treated
animals (Fig. 3b–d), as evaluated by weight decline (p <
0.0001 versus CTRL and p= 0.023 versus HBSS), motor
score (p < 0.0001 versus CTRL and p= 0.001 versus
HBSS) as well as rotarod performance (p < 0.0001 versus
CTRL and p= 0.011 versus HBSS). The transplantation
surgery led to a worsening of motor performance for
about 10 days, during which time the treated rats were not
always able to perform on the behavioural tests. In fact,
during the MSS, the performance of both treated groups
(hNSC and HBSS) was similar (p > 0.5), and was sig-
nificantly worse than that of the CTRL group (p < 0.03).
Fig. 2 Differentiation of transplanted hNSCs within the SOD1 rat
spinal cord. a Representative confocal images showing the
colocalization of the human nuclear antigen (huN) with proliferating
cells (Ki67) and neural phenotype markers (Nestin, GFAP, DCX, btubIII
and PDGFR-a) in transplanted hNSCs at 40DAT. b Quantification of
each markers. Scale bars: 75 μm for the maximum projection images
and 15–25 μm for the colocalization images
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At the LSS stage, the performance of the hNSCs-treated
rats appeared to be stabilised, and was reliably better than
that of the HBSS-treated animals. The motor score was
2.02 ± 0.3 for hNSC and 1.17 ± 0.31 for HBSS at 39DAT
(p < 0.05, Fig. 3c); the rotarod score was 103.37 ± 22.84 s
for hNSC and 30.47 ± 25.99 s for HBSS at 48DAT (p <
0.04, Fig. 3d); and the weight was 323.51 ± 12.56 g for
hNSC rats and 280.12 ± 15.86 g for HBSS rats at 57DAT
(p < 0.04, Fig. 3b). Of note, disease progression was ame-
liorated in hNSCs-transplanted animals, even when
compared with CTRL animals, although this difference
was evident later than relative to the HBSS groups. In
particular, the motor scores were 2.02 ± 0.31 for hNSC
rats and 1.23 ± 0.25 for CTRL at 51DAT (p < 0.05, Fig. 3c);
the rotarod score was 96.62 ± 24.13 s for hNSC rats and
23.65 ± 20.94 s for the CTRL group at 57DAT (p < 0.03,
Fig. 3d); and weights were 313.89 ± 13.04 g for hNSC rats
versus 269.96 ± 12.59 g for the CTRL group at 63DAT (p
< 0.02, Fig. 3b).
At E-ST (60DAT), while animals in both control groups
had almost completely lost their motor ability (rotarod
and motor score values= 0), motor function was still
partially preserved in the hNSCs-transplanted animals
(50% of motor score, 1.93 ± 0.34, Fig. 3c), as was their
ability to run on the rod (30% of rotarod performance,
93.47 ± 24.54 s, Fig. 3d).
hNSCs induce a significant decrease in the degeneration of
MNs
The functional data were validated by histopathological
findings, which mirrored a significant delay in the
degeneration process of MNs at 40DAT, as demonstrated
by the results of stereological analysis of MN cell density
in the treated region of the spinal cord (Fig. 4).
Fig. 3 Extention of lifespan and slow-down of behavioral deterioration in hNSCs-treated rats. a Kaplan–Meier survival probability analysis, n=
14 for untreated SOD1 (CTRL, green) and n= 5 for HBSS-treated SOD1 (HBSS, red) and hNSCs-treated SOD1 (hNSCs, blue). b–d Trend of weight,
motor score and rotarod performance decline in CTRL (green, n= 22), HBSS (red, n= 15) and hNSCs (blue, n= 15) rats. The curves were obtained by
appliyng statistical modelling of the progressive reduction of the mean weight value (b) or mean motor score value (c) or the mean time spent on
the rotarod (d). Where the hNSCs-treated animals showed a statistically significant improved value respect to CTRL is indicated with asterisks above
the green line, respect to HBSS animals with asterisks above the red line. On the x axis, the days are shown after ESS and coloured bars indicate the
stage of the disease. *p ≤ 0,05; **p ≤ 0,01; ***p ≤ 0,001. Data are reported as mean ± SEM
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Preservation of MNs was maximal around the cell injec-
tion site, namely within segments L3–L4: hNSCs-treated
SOD1 rats displayed a significantly higher density of MNs
(336.65 ± 28.73 MNs/mm3) relative to control groups
(204.25 ± 19.47 for CTRL p ≤ 0.01 and 231.60 ± 24.05 for
HBSS p ≤ 0.05; Fig. 4a, b). To corroborate the beneficial
effect of hNSCs, we evaluated the presence of misfolded
SOD1 deposits by using the SEDI antibody30,31. Of note,
in the anterior horns of hNSC animals, at 40DAT, SOD1
deposits appeared reduced respect to both control groups
(Fig. 4c), in which SOD1 was apparent and predominantly
accumulated within MNs (Fig. 4c, arrow).
hNSCs immunomodulate reactive astrogliosis and
microgliosis
To assess whether hNSCs can influence resident
inflammatory cells, we evaluated the morphology and
quantity of GFAP+ cells (for astrogliosis, Fig. 5) and of
Fig. 4 Reduction of motor neurons degeneration and accumulation of misfolded SOD1 in hNSCs-treated SOD1 rats. a Chart showing the
motor neurons density (MNs/cm3) in the L1-L4 tract, n= 5 for each experimental group. *p ≤ 0.05; **p ≤ 0.01. Data are reported as mean ± SEM. b
Representative images of the MNs in the anterior horn (AH) of the spinal cord (Nissle staining). Scale bars: 100 μm. c Representative confocal images
of misfolded SOD1 deposits in the AH of CTRL, HBSS or hNSCs rats (n= 3/group) at 40DAT. Scale bars: 20 μm
Zalfa et al. Cell Death and Disease          (2019) 10:345 Page 6 of 15
Official journal of the Cell Death Differentiation Association
Fig. 5 Reduction of astrogliosis in hNSCs-treated rats. a Representative confocal images of activated astroglial cells (GFAP+) in the anterior horn
(AH) of CTRL, HBSS or hNSCs rats. b Chart showing the quantification analysis of the number of GFAP+ cells in the anterior horn, anterior funiculus or
whole (anterior horn, anterior funiculus and lateral funiculus). Scale bars: 75 μm
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Iba1+ and CD68+ cells (for microgliosis, Figs. 6, 7), in the
L3–L4 segments of the spinal cord around the grafted
area, and looked for how the activation correlated to
disease progression (at 15, 40DAT and E-ST). To deter-
mine the magnitude of the effect that hNSCs have on the
different components of the motor system, we separately
evaluated the anterior horns (which contain the somata of
α-MNs) and the white matter, specifically the anterior and
lateral funiculi (which comprise the descending fibres of
the pyramidal and extrapyramidal tracts, respectively).
These areas, colonised by transplanted hNSCs (Fig. 1c–e),
are directly involved in the neuronal circuitry for motor
control and majorly affected by the inherent degeneration
process in this animal model of ALS12.
Astrogliosis
At 15DAT, in both control groups, almost all the
astrocytes in the anterior horns were in a reactive state,
displaying hypertrophic and thick processes strongly
immunopositive for GFAP (Fig. 5a, arrows). At 40DAT
and at E-ST, astrogliosis was further enhanced (Fig. 5a,
arrowheads). In contrast, in hNSC-transplanted SOD1
rats, the majority of astrocytes displayed thinner processes
and a smaller soma. These morphological differences
between animal groups were more evident at 40DAT (Fig.
5a; Supplementary Fig. 2A). A similar immunomodulatory
effect of transplanted hNSC was also observed in white
matter regions (Supplementary Fig. 2B). The quantitative
analysis mirrored the morphological observations (Fig.
5b) by demonstrating, as early as 15DAT, a statistically
relevant reduction of the number of astrocytes in hNSCs-
transplanted SOD1 rats relative to the HBSS-treated
group, both in the anterior horns and funiculi; this dif-
ference became more striking at 40DAT (p < 0.01 versus
untreated SOD1 and p < 0.05 versus HBSS-treated SOD1).
Finally, at E-ST, the hNSC-transplanted rats still showed a
lower level of astrogliosis in the white matter tracts (Fig.
5b, anterior funiculi and whole, p < 0.05 versus the same
in untreated SOD1 rats). To note, hNSC-treated animals
reached E-ST at a significantly later age (mean age, P204)
compared with control animals (mean age P170).
Astrocyte fractions were comparable at the mid-to-late
stage transition (15 to 40DAT) in most animals that
belonged to the same treatment group, but had decreased
at E-ST, likely due to generalised cell damage that also
involved astrocytes32–34.
Microgliosis
The immunomodulatory effect of hNSCs on the
microglial component was mostly marked at 40DAT. In
fact, we observed that at 15DAT, Iba1+microglial cells
displayed thick, rough prolongations (Fig. 6a, arrows) and
were comparable among all groups. This inflammatory
process was consistently enhanced within the 15 to
40DAT transition in the spinal cord of control groups. At
these time points, Iba1+ cells were hypertrophic, with
short processes and an “amoeboid” (activated) morphol-
ogy (Fig. 6a, arrowheads; Supplementary Fig. 3A). In
contrast, at 40DAT, in the anterior horns of hNSCs
treated SOD1 rats, the switch of microglial cells to an
enhanced activated state, appeared arrested (Fig. 6a;
Supplementary Fig. 3A). No difference was observed
between the groups at the E-ST (Fig. 6a). A similar pattern
was also observed in white matter regions (Supplementary
Fig. 3B). The quantification analysis correlated with the
morphological observations, showing the reduced num-
bers of Iba1+ cells in hNSC-transplanted SOD1 rats at
40DAT (from p ≤ 0.05 to p ≤ 0.01 versus controls, Fig. 6b).
To evaluate the contribute of activated microglial/
macrophages cells, we analysed the expression of CD68.
Consistent with the above findings, CD68+microglial
cells displayed a morphologically activated state in the
spinal cord of each experimental group (Fig. 7a; Supple-
mentary Fig. 4A), and the CD68 protein co-localised with
the pan-microglial antigen Iba1 (Supplementary Fig. 4B).
The quantitative analysis confirmed that, at 40DAT, the
number of activated CD68+ cells was reduced in hNSC-
treated animals (p < 0.05 in the anterior horn, Fig. 7b).
Discussion
ALS is a multifactorial disease with no available effective
cure1,2. We present compelling evidence that intraspinal
delivery of hNSCs ameliorates the course of the disease,
delays the deterioration of motor functions and extends
overall survival in a transgenic rat model of ALS. These
favourable symptomatic outcomes (that peaked between
40–60DAT) are accompanied by a delay in the accumu-
lation of histopathological markers of ALS, referable to a
hNSCs pleiotropic mode of action35–38. In particular,
anterior horn MNs are preserved and astrogliosis and
microgliosis are reduced in the spinal cord tract of hNSC-
treated SOD1 rats.
Relevance to clinical studies
The positive effects of hNSCs transplantation on disease
progression in models of ALS have been widely docu-
mented11–15,22,39,40, but the variability in the methodologies
used to derive and expand hNSCs has often confounded
interpretations. Our data are remarkably relevant because
we used hNSCs derived with the AIFA-authorised protocol
(aM 154/2018) that has been used for the ALS Phase I trial
(EudraCT:2009–014484–39 trial)23,26,41. The rigorous
experimental conditions that we describe in this study
mimic the clinical setting with the goal of having our results
be relevant to future phase II studies in patients.
In preclinical studies, often stem cells are delivered at
the pre-symptomatic stage of the disease, in order to
maximise the window during which the cells can exert
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Fig. 6 Reduction of microgliosis in hNSCs-treated rats. a Representative confocal images of activated microglial cells (Iba1+) in the anterior horn
(AH) of CTRL, HBSS or hNSCs rats. b Chart showing the quantification analysis of the number of Iba1+ cells in the anterior horn, anterior funiculus or
whole (anterior horn, anterior funiculus and lateral funiculus). Scale bars: 75 μm
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Fig. 7 Reduction of activated CD68+ microglial cells in hNSCs-treated rats. a Representative confocal images of activated microglial cells
(Iba1+ CD68+) in the anterior horn (AH) of CTRL, HBSS or hNSCs rats. b Chart showing the quantification analysis of the number of CD68+ cells in
the anterior horn, anterior funiculus or whole (anterior horn, anterior funiculus and lateral funiculus). Scale bars: 75 μm
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their therapeutic actions12,15,40. But while this approach is
optimal for obtaining positive results in a basic research
setting, translating this therapeutic sequence—which
involves making transplantations prior to the appearance
of symptoms—to the bedside is clearly not realistic,
because ALS diagnosis only occurs at the symptomatic
stage. We thus chose to treat the animals when the initial
motor symptoms of the pathology are recognisable. But
despite the treatment being administered after disease
onset and a corresponding reduction of the therapeutic
window, hNSC-treated rats showed better motor perfor-
mances compared with controls.
Because intraspinal cord injection partially disrupts the
parenchymal structure and triggers the inflammatory
reaction, worsening the animal’s motor functions42,43, we
also compared the symptomatic progression of SOD1 rats
treated with hNSCs to untreated SOD1 rats (CRTL)—the
goal here was to control for possible detrimental effects of
the injection procedure. As expected, the motor perfor-
mances of treated animals were reduced compared with
CTRL, in the immediate post-injection period. Notwith-
standing, as early as 50DAT, hNSC-transplanted rats
completely overcame the surgery-induced impairment,
displaying a significantly improved motor performance
relative to both control groups. Under our stringent
experimental conditions, a symptomatic improvement
relative to untreated animals has never been documented,
further strengthening the clinical relevance of our
approach and supporting our surgical procedure.
Symptomatic improvement
Intra-spinal delivery is aimed at preventing the degen-
eration of secondary MNs that leads to paralysis, and
ultimately to respiratory failure. The major limitation of
this strategy is that therapeutic hNSCs are supplied to a
restricted area of the motor control system, while ALS
affects the entire motor neuraxis, including upper MNs in
the cortex. Notwithstanding this, the survival of hNSC-
treated rats was extended by ~30 days relative to control
animals. Similar studies have reported a smaller increase
in lifespan (between 11 and 17 days14,15 or no effect on
survival12).
Extensive migration and integration and no rejection
hNSCs migrated radially, from the anterior horn into
the lateral and anterior funiculi of the white matter
(comprising descending extrapyramidal and pyramidal
fibres) as well as along the rostro-caudal axis, reaching the
thoracic and sacral segments. The observation that dif-
ferent hNSC lines display an intrinsic variability in
migration (unpublished data), suggests the necessity of an
accurate evaluation of this parameter in preclinical pha-
ses, in order to improve the therapeutic efficacy of these
stem cells in phase II trials.
Moreover, under conditions of transient immunosup-
pression, hNSCs are able to survive in SOD1 rats, up to
the ESS, with no rejection and no adverse immunological
effects due to cross-species differences, consistently with
our previous studies44. Our findings validate the wide
therapeutic potential of hNSC in that they show virtually
zero immunogenicity. This aspect, of course, must be
further verified with regard to the absence of rejection
after the cells have been transplanted.
The slow-down of symptomatic worsening corresponds to
an amelioration of the pathogenic environment including
neuroinflammation blunting by hNSCs
Here we present, for the first time, a time course ana-
lysis to evaluate the progression of astrogliosis and
microgliosis in order to reinforce the notion that the
inflammatory cascade is an efficacious therapeutic target
for the transplanted hNSCs44–46. Our analysis points to a
correspondence between the delay in worsening of
symptoms observed in the hNSCs-treated SOD1 rats and
the reduced inflammatory response in the anterior horns.
In fact, at 15DAT, the three experimental groups showed
minimal differences, concerning both neuroinflammation
and behavioural symptoms. While at 40DAT, activated
astroglial and microglial cells were significantly reduced in
hNSCs-treated rats, at the morphological level as well as
by quantitative evaluation. These differences were
accompanied by evidence of the first symptomatic bene-
fits (motor score at 40DAT), which continued through the
subsequent evaluation period (40–60DAT).
Within the same time frame (40DAT), the misfolded
SOD1 deposits were less present in the anterior horns of
hNSCs-transplanted rats respect to both control groups.
Although preliminary, this observation is consistent with
the hypothesis that hNSCs ameliorate the pathogenic
surroundings of MNs, in fact it is now well established
that misfolded SOD1 accumulation is a key element of
SOD1-mediated ALS, and that the reduction of its level
determines significant beneficial effects in preclinical
model47,48.
Hefferan et al.12 have demonstrated that axons of des-
cending primary MNs in the SOD1 rat model are
impaired. Notably, these degenerative processes are more
evident in the lateral (mostly rubrospinal tract) and
anterior (pyramidal pathway) white matter. In addition,
when the corticospinal tract is damaged, lateral columns
provide de novo innervating cells to MNs in the anterior
horns49,50, suggesting that lateral columns contribute to
recovery mechanisms following degenerative insults to
the motor system. Considering the extensive migration of
hNSCs from the anterior horns to the aforementioned
areas (lateral and anterior white matter), we evaluated and
quantified a significant reduction of neuroinflammation in
all these areas that were maintained until the late stages of
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the disease, with an obvious amelioration of the local
pathogenic environment. Given the reports of axon die-
back (i.e., axonal degeneration might occur prior to the
onset of symptoms) in the pathogenesis of ALS51–53, the
amelioration of parenchymal milieu surrounding distal
axons—such as the reduction of neuroinflammation—
could retrogradely affect the MN soma located in the
motor cortex. Thus, it probably contributes to the gen-
eralised beneficial effect of hNSCs, in spite of their local
delivery.
In conclusion, our study points to the potential ther-
apeutic efficacy of using clinical-grade hNSCs that are
already in use in a clinical trial on ALS patients. Our
findings validate that extensive and non-invasive intra-
parenchymal transplantation of hNSC lines, which have
been cultured under standardised conditions, can work as
a therapy for ALS.
Materials and methods
Animal model—Ethics Statement and Institutional Animal
Care and Use Committee (IACUC) approvals
SOD1 transgenic male rats (Taconic, USA) were bred
with Sprague Dawley female rats (Harlan Laboratories,
USA) to obtain and maintain hemizygous transgenic
progeny—the transgenic offspring were identified by
polymerase chain reaction (PCR), in which DNA
extracted from the tails at P22 was amplified and used to
verify the presence of the exogenous human SOD1
gene28. All animal care and experimental procedures
were carried out according to the current national and
international animal ethics guidelines, and were
approved by the Italian Ministry of Health (authorisa-
tion number # 286/2013 -B).
Preparing hNSCs for implantation
The hNSCs used in the study have been produced and
characterised in the Cell Factory and Biobank of Santa
Maria Hospital (Terni, Italy), authorised by the Italian
Medicine Agency (AIFA) for the production of hNSCs to
be used for clinical trials (aM 54/2018). The methodology
applied to isolate, expand, characterise and cryopreserve
the lines is based on the Neurosphere Assay26,41,54, and
has been used for the production of the cells utilised in
phase I trials for Amyotrophic Lateral Sclerosis patients
(NCT0164006723) and for Secondary Progressive Multiple
Sclerosis patients (NCT03282760, ongoing).
The entire production process, starting from tissue
procurement to cryopreservation is compliant to cGMP
guidelines and approved by AIFA. The hNSCs are
obtained from foetal brain tissue derived from fetuses that
underwent miscarriage or natural in utero death upon
receiving the signed informed consent from the mother.
Forty-eight hours prior to implantation, hNSCs were
plated in the growth medium at a concentration of 10,000
cells/cm2. On the day of surgery, hNSCs were collected by
centrifugation, viable cells were counted by Trypan blue
exclusion criteria, and the correct number of cells were
re-suspended in HBSS for the transplant.
Experimental groups
SOD1 transgenic male rats were randomly divided into
three experimental groups: (i) transplanted with hNSCs
(hNSC rats, n= 15); (ii) treated with HBSS (HBSS rats, n=
15) and (iii) untreated (CTRL rats, n= 22). An additional
group of non-transgenic littermates (wild-type, WT, n= 9)
were used as controls for symptomatic evaluation of the
colony. Tacrolimus (FK506) and cyclosporine (cyclosporin
A) are the principal immunosuppressive drugs that have
been applied for solid organ transplantation55,56 and have
been translated to stem cell treatments for PD57 and ALS22.
In animal models, despite differences in potency, both drugs
showed excellent survival rates for grafts across many
comparative studies58,59. Our previous results44,45 showed
that hNSCs can survive—without signs of rejection—in the
rat brain up to 6 months under transient immunosup-
pression treatment, with cyclosporin A. On the bases of
these results, we applied the same immunosuppressive
treatment with administration of cyclosporine A (15mg/kg/
day subcutaneous; Sandimmne, Novartis) that was initiated
on the day of transplantation and continued for 15 days
after surgery (for all animal groups).
Implanting hNSCs into spinal cord
Cells were transplanted at the early-symptomatic stage
(ESS) of the disease, i.e., when the SOD1 rats presented
with initial signs of a decrease in limb control and/or with
initial failure on the rotarod. Animals were anaesthetised
with isofluorane (1.5–2% maintenance; in room air),
placed in a spinal clamp apparatus (David Kopf Instru-
ments, Tujunga, CA), and a partial L1–L2 laminectomy
was performed. The cells (or HBSS) were injected bilat-
erally with use of a Hamilton syringe (33-gauge needle)
into the ventral horns of the L3–L4 segments of the cord.
Injections were made on both sides, at four sites, set 1 mm
apart. At each site, we delivered 1 μl of HBSS containing
the hNSCs (100,000 cells/μl), or 1 μl of HBSS only (in
control group), applied over 60 s; the needle was left in
place for an additional 180 s, then withdrawn. After all
injections were completed, the incision was sutured and
animals were placed back into their cage with ad libitum
access to food and water.
Assessment of neurological function and disease
progression
Motor functions were evaluated using three different
tests: rotarod, motor score and body weight27,28— these
tests allowed us to define the ESS, the MSS, the LSS and
the E-ST of the disease (see details in the Results section).
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All behavioural measures were recorded by individuals
blinded to the treatment group.
Rotarod test
The rotarod test was used to evaluate general motor
coordination, and the strength and balance of the animal.
Starting on P70, animals were trained on the rotating rod,
increasing the sped from 4 to 22 rotations per min within
300 s; the rats were trained three times a week, and then
tested twice a week27). Each test consisted of three runs
on the rotarod (lasting a maximum of 300 s) and perfor-
mance was quantified by calculating the mean time
(seconds) spent on the rod.
Motor score
Rats were scored twice a week, starting on P70. Hind-
limb splay defects were scored on a scale of 0–4, with 4=
normal; 3.5= onset of hind-limb splay defect; 3=
abnormal gait; 2= partial hind-limb paralysis (first signs
of dragging); 1= hind-limb paralysis plus forelimb
weakness; 0= significant fore- as well as hind- limb
paralysis.
Body weight evaluation
Rats were weighed twice a week, starting on p70.
Statistical evaluation of symptomatic analysis
Temporal evolution of rotarod performance, motor
score and body weight were assessed using a longitudinal
linear model, accounting for the repeated, unequally
spaced, measurements design using a spatial power cov-
ariance matrix. Nonlinear evolutions were modelled by
adding both linear and time quadratic terms into the
model. Pairwise group comparisons (CTRL vs. HBSS vs.
hNSCs) of overall and specific time points were assessed
with use of suitable statistical contrasts. Estimated means,
and their temporal evolution, were graphically repre-
sented. Time to death analysis was conducted with use of
a proportional hazard Cox regression model, and risks
were reported as hazard ratios (HR), along with their 95%
confidence intervals (95% CI). The time variable was
defined as the time between the surgery (or, for CTRL
rats, the time of initial deterioration of symptoms) and the
date of death. Kaplan–Meier curves were also displayed. A
p-value of < 0.05 was considered to be statistically sig-
nificant. All analyses were performed using SAS Release
9.3 (SAS Institute, Cary, NC). Note that we performed a
sensitivity analysis by choosing a CTRL group that pre-
sented, on day 0, a rotarod and motor score value that was
better than that for the hNSC and HBSS animals
(p < 0.05).
Immunohistochemistry
Histological analyses were performed at three time
points: 15DAT, 40DAT and END STAGE. To the scope,
we killed n= 5 animals/time point out of the previously
described experimental group (transplanted with hNSCs,
treated with HBSS and untreated). To retrieve the spinal
cord, animals were euthanized by overdose of anaesthesia
and perfused/fixed with paraformaldehyde solution (4%).
Immunohistochemistry was performed on cryopreserved
coronal sections of the spinal cord fixed in 4% PFA made
up in PBS. Cords were removed, immersed overnight in
4% PFA at 4 °C, cryoprotected in sucrose gradients (10, 20
and 30%) and sectioned at 30 μm on a cryostat. Parallel
series were collected on glass slides. For immunohis-
tochemistry, sections were incubated for 90min with
blocking solution (PBS-1X with 10% normal goat serum
(NGS) and TRITON X-100 at 0.1%) at room temperature,
then immersed overnight in the following primary anti-
bodies, diluted in the blocking solution, at 4 °C: human
nuclei (huN mAb, Millipore), glial fibrillary acidic protein
(GFAP pAb, Dako), Ki67 antigen nuclear (Ki67 pAb,
Monosan), Ionised calcium-binding adapter molecule 1
(Iba1 pAb, Wako), cluster of differentiation 68 (CD68,
mAb, Biorad), doublecortin (DCX, pAb, Santa Crouz),
platlet-derived growth factor receptor-α (PDGFR-α, pAb,
Euroclone), human Nestin (hNestin, mAb, R&D system),
β-tubulin III (β-tubIII, mAb, Covance), anti SOD1
exposed dimer interface (SEDI, pAb StressMarq Biosci-
neces Inc., SPC-206P, generously provided by Corona C.
and Crociara P.). Tissues were rinsed with PBS. Samples
were then incubated for 90 min at room temperature, in
the following secondary antibodies: Alexa Fluor 594- or
488-labelled anti-mouse and/or anti-rabbit (Molecular
Probes). After washing with PBS, the cell nuclei were
labelled with DAPI for 20 min at room temperature.
Finally, the slides were rinsed in PBS, coverslipped, and
left to dry at room temperature in the dark. Micro-
photographs were acquired using a Zeiss Axiovert 200
direct epifluorescence microscope (Axioplan 2, Carl Zeiss,
Jena, Germany) or by confocal microscopy (Leica DM
IRE2 or Nikon).
Stereological counts of MNs
One set of serial sections (every 1050 μm) from each
animal was Nissl-stained for stereological counting.
Nucleoli of MNs in the L1–L4 spinal cord (where cells
were delivered) were identified and counted at 40x in
(hNSC rats, n= 5; HBSS rats, n= 5; CTRL rats, n= 5):
only neurons ≥ 200 μm2 in area (attributable to alpha
motor neurons) and located in a proper position (http://
store.elsevier.com/The-Spinal-Cord/isbn-9780123742
476) were included. A 3.5 -µm guard zone, a 150 -µm ×
150 -µm counting frame size and a 200 -µm × 200 -µm
scan grid size were set. The density of MNs (cells/mm3)
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was calculated by counting cells with the Optical Frac-
tionator stereological technique60, on a computer-
assisted a Nikon Eclipse E600 microscope equipped
with the StereoInvestigator software (MicroBrightField,
Williston, VT, USA). Cells were counted on the com-
puter screen, with the help of an Optronics MicroFire
digital camera.
Quantitative analysis of immunohistochemistry
Surviving transplanted hNSCs were determined by
counting all huN+ cells in serial sections through the
spinal cord sections that spanned the graft area. The total
number of hNSCs was calculated for the entire graft
region, using the Abercombie formula. Data were pre-
sented as the percentage of surviving cells over the total
number of transplanted cells. The full extent of ante-
roposterior migration was calculated by evaluating the
distance between the most proximal and most caudal
sections containing huN+ cells. Differentiation of hNSCs
was assessed by co-localisation of huN reactivity with
markers depicting differentiation of the neural lineage:
Ki67, Nestin, GFAP, DCX, β-Tub III, PDGFR-a. Analysis
was performed on at least three sections within the
transplant area, using three fields (×40 magnification) for
each section.
To determine the numbers of active astroglia and
microglia, we counted cells positive for GFAP, Iba1 or
CD68 and divided by the total number of DAPI-stained
nuclei. Data were quantified on bilateral epifluorescence
images of the anterior horns, anterior funiculi and lateral
funiculi acquired on the camera from at least three sec-
tions within the transplanted area (L3–L4 region).
Statistical analysis was performed by one-way ANOVA.
Data were reported as means ± SEM. Each value repre-
sented the average of n= 5, animals, unless stated
otherwise. Data were not considered statistically sig-
nificant unless indicated in the figures (*p < 0.05, **p <
0.01, ***p < 0.001).
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